4. The Politics of Health

4. The Politics of Health

972 bookmarks
Newest
Eugenics: The sinister ideology behind COVID “normalization”
Eugenics: The sinister ideology behind COVID “normalization”
The headline of the January 12 Bloomberg.com op/ed says it all: “Say Goodbye to Self-Isolating, WFH Mandates, Mass Testing.” The authors boast, “The balance of power between human and virus is shifting. Better armed against a lesser enemy, our species no longer needs to hide in a bunker waiting for a viral wave to pass.
·socialist.ca·
Eugenics: The sinister ideology behind COVID “normalization”
She had a natural remedy for everything — except COVID
She had a natural remedy for everything — except COVID
Red thought “natural” remedies were the cure-all for everything. Nurses are heroes. Not the ones who endanger their patients by refusing to vaccinate during a global pandemic that’s killing millions. Definitely not those. But the 99%+ that are still trying to clean up the mess the anti-vaxxers...
·feeds.feedblitz.com·
She had a natural remedy for everything — except COVID
New Report - Disinformation Doctors: Licensed to Mislead - de Beaumont Foundation
New Report - Disinformation Doctors: Licensed to Mislead - de Beaumont Foundation
Poll: 9 in 10 Americans say doctors should be held accountable for COVID-19 disinformation A new report released today urges state medical licensing bodies to investigate doctors who are deliberately spreading misleading or false COVID-19 information. And an overwhelming majority of the public agree: Nine in 10 Americans say doctors who intentionally spread misinformation about […]
·debeaumont.org·
New Report - Disinformation Doctors: Licensed to Mislead - de Beaumont Foundation
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital, and deaths. Design Test negative case-control study. Setting Community testing for covid-19 in England. Participants 156 930 adults aged 70 years and older who reported symptoms of covid-19 between 8 December 2020 and 19 February 2021 and were successfully linked to vaccination data in the National Immunisation Management System. Interventions Vaccination with BNT162b2 or ChAdOx1-S. Main outcome measures Primary outcomes were polymerase chain reaction confirmed symptomatic SARS-CoV-2 infections, admissions to hospital for covid-19, and deaths with covid-19. Results Participants aged 80 years and older vaccinated with BNT162b2 before 4 January 2021 had a higher odds of testing positive for covid-19 in the first nine days after vaccination (odds ratio up to 1.48, 95% confidence interval 1.23 to 1.77), indicating that those initially targeted had a higher underlying risk of infection. Vaccine effectiveness was therefore compared with the baseline post-vaccination period. Vaccine effects were noted 10 to 13 days after vaccination, reaching a vaccine effectiveness of 70% (95% confidence interval 59% to 78%), then plateauing. From 14 days after the second dose a vaccination effectiveness of 89% (85% to 93%) was found compared with the increased baseline risk. Participants aged 70 years and older vaccinated from 4 January (when ChAdOx1-S delivery commenced) had a similar underlying risk of covid-19 to unvaccinated individuals. With BNT162b2, vaccine effectiveness reached 61% (51% to 69%) from 28 to 34 days after vaccination, then plateaued. With ChAdOx1-S, effects were seen from 14 to 20 days after vaccination, reaching an effectiveness of 60% (41% to 73%) from 28 to 34 days, increasing to 73% (27% to 90%) from day 35 onwards. On top of the protection against symptomatic disease, a further 43% (33% to 52%) reduced risk of emergency hospital admission and 51% (37% to 62%) reduced risk of death was observed in those who had received one dose of BNT162b2. Participants who had received one dose of ChAdOx1-S had a further 37% (3% to 59%) reduced risk of emergency hospital admission. Follow-up was insufficient to assess the effect of ChAdOx1-S on mortality. Combined with the effect against symptomatic disease, a single dose of either vaccine was about 80% effective at preventing admission to hospital with covid-19 and a single dose of BNT162b2 was 85% effective at preventing death with covid-19. Conclusion Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease. Both vaccines showed similar effects. Protection was maintained for the duration of follow-up (6 weeks). A second dose of BNT162b2 was associated with further protection against symptomatic disease. A clear effect of the vaccines against the B.1.1.7 variant was found.
·bmj.com·
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Unverified reports of vaccine side effects in VAERS aren’t the smoking guns portrayed by right-wing media outlets – they can offer insight into vaccine hesitancy
Unverified reports of vaccine side effects in VAERS aren’t the smoking guns portrayed by right-wing media outlets – they can offer insight into vaccine hesitancy
Anti-vaccine activists are using the side effect reporting system to spread fear and misinformation about the COVID-19 vaccines. But the database could also be used as a gauge for public concerns.
·theconversation.com·
Unverified reports of vaccine side effects in VAERS aren’t the smoking guns portrayed by right-wing media outlets – they can offer insight into vaccine hesitancy